• Featured Product
  • KD/KO Validated

PLK1 Polyclonal antibody

PLK1 Polyclonal Antibody for FC, IHC, WB,ELISA

Host / Isotype

Rabbit / IgG


human, mouse, rat





Cat no : 10305-1-AP


PLK, PLK 1, PLK1, Polo like kinase 1, STPK13

Tested Applications

Positive WB detected inMDA-MB-453s cells, HEK-293 cells, U2OS cells, HeLa cells, mouse testis tissue, rat testis tissue
Positive IHC detected inhuman prostate cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive FC detected inHeLa cells

Recommended dilution

Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

The immunogen of 10305-1-AP is PLK1 Fusion Protein expressed in E. coli.

Tested Reactivity human, mouse, rat
Cited Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen PLK1 fusion protein Ag0284
Full Name polo-like kinase 1 (Drosophila)
Calculated molecular weight 68 kDa
Observed molecular weight 62 kDa
GenBank accession numberBC002369
Gene symbol PLK1
Gene ID (NCBI) 5347
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

PLK1(Polo-like kinase 1), also named as PLK and STPK13, belongs to the protein kinase superfamily, Ser/Thr protein kinase family and CDC5/Polo subfamily. PLK1 is a Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of APC/C inhibitors, and the regulation of mitotic exit and cytokinesis.The localization of Polo changes during the cell cycle. In interphase, Polo shows a mostly diffuse cytoplasmic localization. Polo becomes concentrated on centrosomes from early prophase and appears on centromeres or kinetochores from late prophase, before nuclear envelope breakdown (NEB). After anaphase onset, Polo relocalizes to the central spindle and remains enriched at the midbody ring in late stages of cytokinesis (PMID: 29167465).


Product Specific Protocols
WB protocol for PLK1 antibody 10305-1-APDownload protocol
IHC protocol for PLK1 antibody 10305-1-APDownload protocol
FC protocol for PLK1 antibody 10305-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Nat Med

Translation control of the immune checkpoint in cancer and its therapeutic targeting.

Authors - Yichen Xu

ACS Biomater Sci Eng

Stimuli-Responsive and Highly Penetrable Nanoparticles as a Multifunctional Nanoplatform for Boosting Nonsmall Cell Lung Cancer siRNA Therapy.

Authors - Menghao Shi

Cell Cycle

CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.

Authors - Ling Li

Aging (Albany NY)

PLK1 Inhibition alleviates transplant-associated obliterative bronchiolitis by suppressing myofibroblast differentiation.

Authors - Jizhang Yu
  • KD Validated

Oncol Lett

Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition.

Authors - Rui Song

Int J Nanomedicine

pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.

Authors - Menghao Shi